Dr. Melissa Ilardo

We're getting so much better at this.

We're able to do it successfully in lab animals.

And so, yeah, ethically, I mean, it's just –

I think it's also interesting to think about, you know, enhancement versus, you know, like correction. Like at what point, you know, where is the line between those two? So if we're correcting some kind of genetic defect, first of all, some defects, other people might not even see them as defects. They might just see that as variation amongst humans.

I think it's also interesting to think about, you know, enhancement versus, you know, like correction. Like at what point, you know, where is the line between those two? So if we're correcting some kind of genetic defect, first of all, some defects, other people might not even see them as defects. They might just see that as variation amongst humans.

I think it's also interesting to think about, you know, enhancement versus, you know, like correction. Like at what point, you know, where is the line between those two? So if we're correcting some kind of genetic defect, first of all, some defects, other people might not even see them as defects. They might just see that as variation amongst humans.

I think it's also interesting to think about, you know, enhancement versus, you know, like correction.

Like at what point, you know, where is the line between those two?

So if we're correcting some kind of genetic defect, first of all, some defects, other people might not even see them as defects.

They might just see that as variation amongst humans.

So, you know, where is the line between defect, normal, enhanced? And so it's, yeah, it's, I don't know who would make those decisions, right? once the technology is even available to apply that in unborn children. I mean, of course, it would be a dream to prevent disease using these technologies, but it's a slippery slope maybe.

So, you know, where is the line between defect, normal, enhanced? And so it's, yeah, it's, I don't know who would make those decisions, right? once the technology is even available to apply that in unborn children. I mean, of course, it would be a dream to prevent disease using these technologies, but it's a slippery slope maybe.

So, you know, where is the line between defect, normal, enhanced? And so it's, yeah, it's, I don't know who would make those decisions, right? once the technology is even available to apply that in unborn children. I mean, of course, it would be a dream to prevent disease using these technologies, but it's a slippery slope maybe.

So, you know, where is the line between defect, normal, enhanced?

And so it's, yeah, it's, I don't know who would make those decisions, right?

once the technology is even available to apply that in unborn children.

I mean, of course, it would be a dream to prevent disease using these technologies, but it's a slippery slope maybe.

Yeah, depending on the coverage. Yeah, you can sequence a genome for pretty cheap these days.

Yeah, depending on the coverage. Yeah, you can sequence a genome for pretty cheap these days.

Yeah, depending on the coverage. Yeah, you can sequence a genome for pretty cheap these days.